Alps Advisors Inc. trimmed its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 98.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,608 shares of the biopharmaceutical company's stock after selling 310,727 shares during the period. Alps Advisors Inc.'s holdings in Royalty Pharma were worth $269,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of RPRX. Bank of America Corp DE lifted its holdings in Royalty Pharma by 29.0% during the 1st quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company's stock worth $167,696,000 after buying an additional 786,921 shares in the last quarter. Amundi boosted its position in Royalty Pharma by 15.3% in the 1st quarter. Amundi now owns 3,088,773 shares of the biopharmaceutical company's stock valued at $148,168,000 after buying an additional 409,394 shares during the last quarter. Dorsey Asset Management LLC boosted its position in Royalty Pharma by 0.8% in the 1st quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company's stock valued at $109,207,000 after buying an additional 17,101 shares during the last quarter. Hsbc Holdings PLC increased its stake in shares of Royalty Pharma by 2,562.2% in the 1st quarter. Hsbc Holdings PLC now owns 1,544,018 shares of the biopharmaceutical company's stock valued at $74,000,000 after buying an additional 1,486,020 shares during the period. Finally, Robeco Institutional Asset Management B.V. increased its stake in shares of Royalty Pharma by 28.2% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 1,168,427 shares of the biopharmaceutical company's stock valued at $68,189,000 after buying an additional 256,841 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.
Royalty Pharma Stock Performance
Shares of RPRX stock opened at $69.31 on Monday. Royalty Pharma PLC has a one year low of $37.31 and a one year high of $70.37. The stock has a market cap of $39.76 billion, a PE ratio of 57.76, a price-to-earnings-growth ratio of 1.37 and a beta of 0.36. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.29 and a quick ratio of 1.29. The stock has a 50-day moving average of $61.51 and a 200-day moving average of $54.53.
Royalty Pharma Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a $0.2350 dividend. The ex-dividend date is Friday, November 13th. This represents a $0.94 annualized dividend and a dividend yield of 1.4%. Royalty Pharma's payout ratio is currently 78.33%.
Insider Activity at Royalty Pharma
In other news, EVP Marshall Urist sold 4,126 shares of the company's stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $57.10, for a total value of $235,594.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total transaction of $5,853,000.00. Following the sale, the executive vice president directly owned 270,401 shares of the company's stock, valued at $15,826,570.53. This represents a 27.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 208,252 shares of company stock worth $12,324,407 over the last 90 days. Corporate insiders own 18.84% of the company's stock.
Analyst Ratings Changes
RPRX has been the subject of a number of recent research reports. Morgan Stanley boosted their target price on Royalty Pharma from $65.00 to $67.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 7th. Zacks Research upgraded Royalty Pharma from a "hold" rating to a "strong-buy" rating in a report on Wednesday, November 11th. Bank of America reiterated a "buy" rating on shares of Royalty Pharma in a report on Wednesday, August 5th. Weiss Ratings upgraded Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a research report on Monday, September 14th. Finally, JPMorgan Chase & Co. boosted their price objective on Royalty Pharma from $58.00 to $62.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $63.29.
Read Our Latest Report on RPRX
About Royalty Pharma
(
Free Report)
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company's portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Read More
Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.